Treatment with SGLT2 Inhibitors in Patients with Diabetes Mellitus and Extensive Coronary Artery Disease: Mortality and Cardiovascular Outcomes

Chipayo-Gonzales, David; Shabbir, Asad; Vergara-Uzcategui, Carlos; Nombela-Franco, Luis; Jimenez-Quevedo, Pilar; Gonzalo, Nieves; Nuñez-Gil, Ivan; Mejia-Renteria, Hernan; Macaya-Ten, Fernando; Tirado-Conte, Gabriela; Perez-Vizcayno, Maria Jose; Fuentes, Manuel; Escaned, Javier; Fernandez-Ortiz, Antonio; Salinas, Pablo

doi:10.1007/s13300-023-01454-w

Cited by 2 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elsewhere, data suggest that HbA1c may be better sustained with combination therapy, compared with stepwise T2DM treatment, and the debate regarding the advantages of intensive blood-glucose management in reducing adverse CV outcomes continues [ 15 , 16 ]. The beneficial properties of oral glucose-lowering drugs in avoiding or decelerating progression toward macrovascular complications have been demonstrated in many studies and are well recognised in the literature and in current NICE, ADA/EASD, Primary Care Diabetes Europe and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines, which advocate early combination therapy incorporating SGLT2is for appropriate individuals [ 3 , 4 , 8 , 9 , 11 , 16 – 39 ]. Diabetes therapy should aim to provide the maximum protection in the minimum time with the relative risks and side effects considered alongside other chronic diseases/comorbidities.…”

Section: Bridging the Gap Between Guidelines And Clinical Practice: I...mentioning

confidence: 99%

SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review

Seidu,

Alabraba,

Davies

et al. 2024

Diabetes Ther

View full text Add to dashboard Cite

A substantial evidence base supports the use of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in the treatment of type 2 diabetes mellitus (T2DM). This class of medicines has demonstrated important benefits that extend beyond glucose-lowering efficacy to protective mechanisms capable of slowing or preventing the onset of long-term cardiovascular, renal and metabolic (CVRM) complications, making their use highly applicable for organ protection and the maintenance of long-term health outcomes. SGLT2is have shown cost-effectiveness in T2DM management and economic savings over other glucose-lowering therapies due to reduced incidence of cardiovascular and renal events. National and international guidelines advocate SGLT2i use early in the T2DM management pathway, based upon a plethora of supporting data from large-scale cardiovascular outcome trials, renal outcomes trials and real-world studies. While most people with T2DM would benefit from CVRM protection through SGLT2i use, prescribing hesitancy remains, potentially due to confusion concerning their place in the complex therapeutic paradigm, variation in licensed indications or safety perceptions/misunderstandings associated with historical data that have since been superseded by robust clinical evidence and long-term pharmacovigilance reporting. This latest narrative review developed by the Improving Diabetes Steering Committee (IDSC) outlines the place of SGLT2is within current evidence-informed guidelines, examines their potential as the standard of care for the majority of newly diagnosed people with T2DM and sets into context the perceived risks and proven advantages of SGLT2is in terms of sustained health outcomes. The authors discuss the cost-effectiveness case for SGLT2is and provide user-friendly tools to support healthcare professionals in the correct application of these medicines in T2DM management. The previously published IDSC SGLT2i Prescribing Tool for T2DM Management has undergone updates and reformatting and is now available as a Decision Tool in an interactive pdf format as well as an abbreviated printable A4 poster/wall chart. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-024-01550-5.

show abstract

Section: Bridging the Gap Between Guidelines And Clinical Practice: I...mentioning

confidence: 99%

SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review

Seidu,

Alabraba,

Davies

et al. 2024

Diabetes Ther

View full text Add to dashboard Cite

show abstract

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Karakasis,

Fragakis,

Kouskouras

et al. 2024

Clinical Therapeutics

View full text Add to dashboard Cite

Treatment with SGLT2 Inhibitors in Patients with Diabetes Mellitus and Extensive Coronary Artery Disease: Mortality and Cardiovascular Outcomes

Cited by 2 publications

References 32 publications

SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review

SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Contact Info

Product

Resources

About